In an insightful interview with Dr. William Audeh, MD, MS, Chief Medical Officer at Agendia, featured in ONCOLife, we explore the pioneering strides in genomic testing within breast cancer treatment. Dr. Audeh, shares his expert insights on how MammaPrint and BluePrint assays are revolutionizing early-stage breast cancer management by enhancing treatment precision and reducing unnecessary chemotherapy.

Breast cancer genomic testing impact